Abstract: Objective To evaluate the clinical efficacy and safety of docetaxel plus cisplatin sequentially combined S-1 for patients with gastric cancer of ⅢB-ⅢC stage after operation. Methods A total of 32 patients with gastric cancer of ⅢB-ⅢC stage treated with adjuvant chemotherapy 4 weeks after D2 radical resection were analyzed retrospectively. The adjuvant chemotherapy regimen was as follows：docetaxel 75mg／m2 iv d1；cisplatin 25mg／m2 iv d1-d3. Six cycles were applied with 21 days as a cycle. Then S-1 was orally given as follows：80 mg／m2 for 2 times daily from d1-d14 and 21 days were a cycle. S-1 was applied to 1 year after operation. Patients' 3-year survival，3-year recurrence-free survival and adverse reactions were observed. Results All the patients accomplished chemotherapy in plan. The 1-，2-and 3-year survival rate of 32 patients was 90.6％，81.2％ and 65.0％，respectively. The 1-，2-and 3-year recurrence-free survival rate was 90.6％，81.2％ and 50.4％，respectively. The clinical efficacy was not associated with pathological stage，but with number of lymph nodes（P＜0.05）. Patients bearing metastatic lymph nodes three or less had better 3-year survival rate compared with those bearing lymph node more than 3（78.6％ vs. 54.2％, P＜0.05）. Adverse reactions included bone marrow suppression，gastrointestinal symptoms and hair loss，mainly in grade 1-2. Conclusion Docetaxel plus cisplatin sequentially combined with S-1 as adjuvant chemotherapy for gastric patients with high risk can bring better overall survival, recurrence-free survival，and adverse effect are well-tolerated.